Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing

Jones, M S, Murrell, R D and Shaw, I C (1985) Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing. European Journal of Cancer and Clinical Oncology, 21 (5). pp. 553-555. ISSN 0277-5379

Full text not available from this repository.

Abstract

Sodium 2-mercaptoethanesulphonate (MESNA) is a uroprotective agent generally given i.v. to prevent haemorrhagic cystitis during oxazaphosphorine cancer chemotherapy. Oral administration of the drug is described since this might be an important route during long-term oxazaphosphorine treatment. MESNA is absorbed from the GI tract and excreted in the urine (about 41.5% of the dose), peak excretion being 2-3 hr after administration. A proportion of the excreted dose is as free thiols (about 24.2%) and the remainder is as disulphides. MESNA is shown to enhance excretion of cysteine in urine.

Item Type: Article
Schools and Departments: School of Life Sciences > Biochemistry
Subjects: Q Science > QH Natural history > QH0301 Biology
Depositing User: Tom Gittoes
Date Deposited: 25 Mar 2015 14:55
Last Modified: 25 Mar 2015 14:55
URI: http://sro.sussex.ac.uk/id/eprint/52642
📧 Request an update